What Qualifies You for GLP-1: Understanding Eligibility for GLP-1 Receptor Agonists

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonist medications have become increasingly popular for weight management and metabolic health, but not everyone qualifies for treatment immediately. PlexusDx uses evidence-based medical criteria to assess whether semaglutide, tirzepatide, or other peptide therapies are appropriate for your individual situation.

BMI Requirements for GLP-1 Eligibility

Body mass index serves as one key indicator when evaluating GLP-1 candidacy, though it's not the only factor. The FDA initially approved semaglutide for chronic weight management in patients with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. However, PlexusDx evaluates beyond BMI alone—your metabolic markers, insulin resistance patterns, and individual health goals all influence whether GLP-1 therapy makes sense for you.

Some patients with BMI below traditional thresholds still qualify if they have significant cardiometabolic risk factors or established conditions like type 2 diabetes. PlexusDx conducts a comprehensive health assessment that considers your complete medical picture rather than relying solely on a single measurement. This personalized approach ensures that eligible patients receive appropriate therapy while maintaining safety and efficacy standards.

Medical Conditions That Support GLP-1 Treatment

Patients with type 2 diabetes, cardiovascular disease history, or metabolic syndrome often qualify for GLP-1 receptor agonists due to documented health benefits beyond weight loss. Research shows these medications improve blood glucose control, reduce cardiovascular risk, and support sustainable metabolic improvements in patients with chronic weight-related conditions. PlexusDx evaluates whether your specific health conditions align with GLP-1 therapy as part of a comprehensive treatment strategy.

Insulin resistance and prediabetes are additional factors that may qualify you for GLP-1 treatment, even without a diabetes diagnosis. These conditions indicate metabolic dysfunction that responds well to GLP-1 receptor agonist intervention. During your PlexusDx evaluation, your healthcare provider will review your lab results, medical history, and current medications to confirm that GLP-1 therapy supports your health trajectory.

Age and Health Status Considerations

GLP-1 eligibility varies by age, with most programs serving adults 18 and older who meet medical criteria. Your current health status—including liver function, kidney function, and thyroid health—influences whether you can safely begin GLP-1 therapy. PlexusDx requires baseline laboratory assessment to ensure no contraindications exist before starting compounded semaglutide or other peptide medications.

Patients with a personal or family history of thyroid cancer or multiple endocrine neoplasia type 2 are typically excluded from GLP-1 treatment due to safety concerns. Pregnancy and breastfeeding also contraindicate GLP-1 use. PlexusDx performs thorough medical screening during your initial consultation to identify any conditions that would prevent you from safely using these medications.

How PlexusDx Determines Your GLP-1 Eligibility

PlexusDx begins with a detailed medical questionnaire and review of your health history to establish a baseline understanding of your metabolic status. You'll provide information about your weight journey, current medications, existing health conditions, and treatment goals. This initial assessment helps PlexusDx identify whether you're a candidate for compounded semaglutide injection (at $189/mo month-to-month, or from $149/mo on the 6-month plan), oral options, or combination therapies like GLP-Squared.

After your medical review, PlexusDx may recommend the Precision Peptide Genetic Test ($298) to map your unique peptide pathways and personalize your treatment protocol. This genetic assessment analyzes 14 metabolic pathways and 150+ genetic insights related to weight regulation and medication response. The combination of medical evaluation and genetic data ensures that your GLP-1 therapy is tailored to your biology, maximizing effectiveness and safety while keeping your monthly cost flat—your dose may need to go up, but your price won't.

Medications That May Disqualify or Limit GLP-1 Use

Certain medications interact with GLP-1 receptor agonists or create safety concerns that may limit your eligibility. Medications that slow gastric emptying, sulfonylureas, or insulin may require dose adjustments or additional monitoring when combined with GLP-1 therapy. PlexusDx reviews your complete medication list during the eligibility assessment to identify potential interactions and determine whether adjustments are necessary.

Medications for other weight loss or metabolic conditions typically require discontinuation before starting GLP-1 treatment to prevent adverse effects. PlexusDx works with your healthcare team to coordinate safe transitions between medications. Your eligibility may also depend on whether your current medications can be safely continued, modified, or paused to support your GLP-1 therapy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is the minimum BMI to qualify for GLP-1 treatment with PlexusDx?

While a BMI of 30 or higher is a traditional threshold, PlexusDx evaluates each patient individually based on their complete health profile. Patients with a BMI of 27 or higher who have weight-related conditions, or those with cardiometabolic risk factors regardless of BMI, may qualify. Your eligibility depends on your specific health circumstances, not a single number.

Can I qualify for GLP-1 if I don't have diabetes?

Yes, many patients without diabetes qualify for GLP-1 therapy based on BMI, insulin resistance, cardiovascular risk, or metabolic syndrome. Research demonstrates that GLP-1 receptor agonists provide weight loss and metabolic benefits for patients across a wide range of health profiles. PlexusDx evaluates non-diabetic patients using the same comprehensive medical criteria as those with diabetes.

How long does the PlexusDx eligibility evaluation take?

PlexusDx typically completes the initial medical assessment and eligibility determination within a few business days of your submitted questionnaire and lab information. Once approved, you can begin treatment with compounded semaglutide injection at $189/mo (or $149/mo on the 6-month plan) or other medication options within 1-2 weeks. The entire process from application to first dose is streamlined for speed and convenience.

Are there health conditions that automatically disqualify me from GLP-1?

Personal or family history of thyroid cancer, multiple endocrine neoplasia type 2, and certain severe kidney or liver diseases may disqualify you from GLP-1 therapy. Pregnancy and breastfeeding also contraindicate these medications. PlexusDx will identify any disqualifying factors during your medical review and discuss alternative options if necessary.

Does the Precision Peptide Genetic Test change my eligibility for GLP-1?

No — the Precision Peptide Genetic Test does not predict your response to GLP-1 medications or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437) and MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Glp Receptor 1 Agonists
• Glp 1 Receptor Agonists For Weight Loss
• Glp 1 Receptor Agonist List
• Glp 1 Receptor

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.